Liquid chromatography detection method for related substances in bisoprolol-levamlodipine tablet
By optimizing liquid chromatography, the problem of difficult separation of 21 impurities in bisoprolol lemulodipine tablets was solved, efficient impurity separation and quantitative analysis were achieved, and the accuracy and sensitivity of drug quality control were improved.
Patent Information
- Application Number
- CN202410960520.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art cannot detect 21 impurities in bisoprolol lemulodipine tablets at the same time, and it is difficult to separate the degraded impurities from the process impurities, affecting drug quality control.
Using optimized liquid chromatography, the column, mobile phase, detection wavelength and gradient elution program can be adjusted to achieve 21 impurities simultaneous detection, improving the resolution and detection accuracy of impurities, ensuring the baseline of the main peak and impurity peak Separation.
Effective separation and quantitative analysis of 21 impurities were achieved, with a resolution of more than 2.5, which could meet the import registration standards and improve the accuracy and sensitivity of drug quality control.
Smart Images

Figure CN118914387A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of impurity detection, and particularly relates to a liquid chromatography detection method for related substances in bisoprolol levamlodipine tablets. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Bisoprolol levamlodipine tablets are used as an alternative treatment for hypertension in patients who are currently taking a single drug at the same dose as the compound preparation and whose blood pressure is well controlled. It is a compound preparation, and each component contains a large amount of degradation impurities and process impurities, such as:
[0004] Degradation principle of amlodipine impurity D: secondary amine and ortho-double bond have strong activity and are easily broken and rearranged by light, oxidation, high temperature, etc. Its degradation reaction is as follows:
[0005]
[0006] Degradation principle of the impurities added by amlodipine and fumaric acid: The primary amine in amlodipine and the double bond in fumaric acid are highly active and are easily affected by light, oxidation, high temperature, etc. The double bond of fumaric acid breaks and reacts with the primary amine of amlodipine. The degradation reaction is as follows:
[0007]
[0008] The main degradation impurity in the acid destruction test is the known impurity bisoprolol impurity A. The degradation principle of bisoprolol impurity A is that the ether bond in bisoprolol undergoes a cleavage reaction under the catalysis of high temperature and acid. The degradation reaction is as follows:
[0009]
[0010] The main degradation impurities in the high temperature destruction test are known impurities (Amlodipine Impurity J, Amlodipine Impurity K, Amlodipine Impurity L). The above impurities appear in groups, among which Amlodipine Impurity L is the most important degradation impurity.
[0011] Degradation principle of impurities J, K, and L of amlodipine: The primary amino group in amlodipine is highly active. Under the catalysis of high temperature, it falls off and undergoes a ring-forming reaction with the secondary amine. Due to the large energy increase caused by high temperature, the rearrangement reaction of nitrogen and oxygen heterocycles continues. The degradation reaction is shown below:
[0012]
[0013] The structural formulas of the impurities are as follows.
[0014]
[0015]
[0016]
[0017]
[0018] At present, the pharmacopoeias, reference documents and other patents of various countries only have detection methods for controlling several impurities separately, which cannot realize the simultaneous detection of 21 impurities in bisoprolol levamlodipine tablets. At the same time, due to the large number of degradation impurities and process impurities, it is difficult to effectively separate the impurities of the two components by conventional methods. Therefore, it is also difficult to realize the simultaneous detection of 21 impurities by a single method, which affects the control of drug quality. Summary of the invention
[0019] In order to solve the above problems, the present invention provides a conventional liquid chromatography detection method for related substances of bisoprolol levoamlodipine tablets. The present invention effectively separates the main degradation impurities from the process impurities through optimization, and the blank auxiliary materials and solvents do not interfere with the determination, thereby improving the specificity of the determination of related substances and the separation degree of each impurity. The present invention can simultaneously detect 21 impurities in bisoprolol levoamlodipine tablets, and the detection method has the characteristics of strong specificity, good accuracy, high sensitivity, excellent separation degree, and wide detection of impurities, which is conducive to strengthening the quality control of each impurity in the detection of bisoprolol levoamlodipine tablets, thereby improving the quality control of bisoprolol levoamlodipine tablets.
[0020] At the same time, the bisoprolol levamlodipine tablets of the present invention are subjected to forced degradation tests under extraordinary conditions such as strong acid, strong alkali, oxidation, high temperature, light, and ultraviolet light. The main peak and the adjacent peaks of the impurities can be well separated (the separation degree is greater than 1.5), and the peak purity results show that the main peak is a single pure peak (no impure substances are detected).
[0021] In order to achieve the above object, the present invention adopts the following technical solution:
[0022] The first aspect of the present invention provides a liquid chromatography test method for related substances in bisoprolol levamlodipine tablets, comprising:
[0023] Grind the bisoprolol levamlodipine tablets, stir, dilute to volume, centrifuge, take the supernatant, filter, and obtain the test solution;
[0024] Prepare reference solutions of various impurities respectively;
[0025] The test solution and the reference solution are tested by liquid chromatography to confirm the content of each impurity;
[0026] Among them, the impurities are amlodipine impurities A, B, D, E, F, G, H, J, K, L, bisoprolol impurities A, B, E, G, L, R, S, T, 8, 10, and amlodipine and fumaric acid addition impurities.
[0027] In some embodiments, the chromatographic column uses octadecylsilane bonded silica gel as a filler, and is a C18 column.
[0028] In some embodiments, mobile phase A is 0.05 mol / L diammonium phosphate solution containing 0.05% perchloric acid, and the pH value is adjusted to 4.5 with phosphoric acid; mobile phase B is acetonitrile containing 0.1% phosphoric acid.
[0029] In some embodiments, the detection wavelengths are 226 nm and 254 nm.
[0030] In some embodiments, the column temperature is 30°C.
[0031] In some embodiments, the flow rate is 1.0 ml per minute.
[0032] In some embodiments, the injection volume is 20 μl.
[0033] In some embodiments, the gradient elution program is: 0-25 min, mobile phase A 90%-65%; 25-45 min, mobile phase A 65%-30%; 45-60 min, mobile phase A 30%; 60-61 min, mobile phase A 30%-90%; 61-75 min, mobile phase A 90%, where % is volume percentage.
[0034] In some embodiments, the concentration of the test article is 0.08%-1.2%.
[0035] In some embodiments, the concentration of the control substance is 0.08%-1.2%.
[0036] Beneficial effects of the present invention
[0037] (1) The present invention can effectively separate 21 kinds of degradation impurities and process impurities. The main peak and the adjacent impurity peaks, and the impurity and the adjacent impurity peaks can achieve baseline separation. The separation degree is greater than 2.5, and the theoretical plate number is greater than 3000. Impurities can be quantitatively analyzed and controlled.
[0038] (2) Compared with the import registration standard, the separation degree of all impurities in the method of the present invention can reach 1.5 or more, while the import registration standard cannot effectively separate the impurities, the separation degree of bisoprolol and bisoprolol impurity K is lower than 1.0, and the total impurity K can only be controlled using a wavelength of 254nm, and the amlodipine impurity J and the amlodipine impurity K are overlapped, and accurate quantitative analysis cannot be performed. The method of the present invention can not only use a single wavelength to control the bisoprolol impurity K, but also can effectively separate all impurities, and the separation degree is greater than 1.5.
[0039] (3) The present invention is compared with the related substances in the Chinese Pharmacopoeia single prescription (bisoprolol fumarate), and the separation degree of bisoprolol and bisoprolol impurity K is lower than 1.0, and the added impurity overlaps with the amlodipine impurity F and cannot be effectively separated. The method of the present invention has a separation degree of more than 1.5 for each impurity and can be baseline separated.
[0040] (4) The present invention is compared with the related substances of the Chinese Pharmacopoeia single prescription (amlodipine besylate). The method is isocratic elution. Bisoprolol and its impurities are both eluted within the first 20 minutes. Bisoprolol and bisoprolol impurity K have overlapping separation degrees, and the separation degree is low. Amlodipine impurity J, amlodipine impurity K, and amlodipine impurity L cannot be eluted, and impurity control cannot be performed. The present method can elute all impurities and can achieve baseline separation, and the separation degree is greater than 1.5. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention, and the exemplary embodiments of the present invention and their description are used to explain the present invention and do not constitute improper limitations on the present invention.
[0042] Figure 1 It is a liquid chromatogram of Example 1 of the present invention, wherein A: test solution, B: impurity mixed solution (PH4.5), C: bisoprolol impurity mixed solution, D: amlodipine impurity mixed solution, E: bisoprolol impurity A and bisoprolol impurity B mixed solution;
[0043] Figure 2 It is the liquid chromatogram of comparative example 1 of the present invention;
[0044] Figure 3 It is the liquid chromatogram of comparative example 2 of the present invention; wherein, impurities R, L, K, G, E, A, and B are all impurities in bisoprolol fumarate.
[0045] Figure 4 It is the liquid chromatogram of Comparative Example 3 of the present invention;
[0046] Figure 5 It is the liquid chromatogram of Comparative Example 4 of the present invention;
[0047] Figure 6 The liquid chromatogram of Comparative Example 5 of the present invention, wherein the upper half is bisoprolol impurity and the lower half is amlodipine impurity, with the impurity mixed solution baseline as the boundary;
[0048] Figure 7 It is the liquid chromatogram of Comparative Example 6 of the present invention;
[0049] Figure 8 It is the liquid chromatogram of Comparative Example 7 of the present invention;
[0050] Fig. 9 It is the liquid chromatogram of Comparative Example 8 of the present invention;
[0051] Fig.10 It is the liquid chromatogram of Comparative Example 9 of the present invention;
[0052] Fig.11 This is the liquid chromatogram of Comparative Example 10 of the present invention;
[0053] Fig.12 This is the liquid chromatogram of Comparative Example 11 of the present invention;
[0054] Fig.13 It is the liquid chromatogram of the specific experiment of the present invention. DETAILED DESCRIPTION
[0055] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0056] As mentioned above, currently, there are only detection methods for controlling several impurities separately in the pharmacopoeias, reference documents and other patents of various countries, and there is no method that can simultaneously control 21 impurities in bisoprolol levoamlodipine tablets. Therefore, in the process of new drug research and development, in response to the need for drug quality control, the inventors have invented a method that can simultaneously control 21 impurities in bisoprolol levoamlodipine tablets.
[0057] In view of this, in the process of new drug research and development, the inventors invented a method that can simultaneously control 21 impurities to meet the needs of drug quality control.
[0058] The quantitative method used was the principal component self-control method with correction factor.
[0059] The present invention systematically optimizes the above detection parameter conditions, and finally obtains an isomer detection method with the advantages of strong specificity, high sensitivity, small sample dosage, good repeatability of quantitative limit, high accuracy, strong durability, simple instrument operation, and applicability to most laboratories.
[0060] The application is specifically to determine and evaluate the presence and content of impurities in bisoprolol levamlodipine tablets.
[0061] The present invention will be further described in detail below in conjunction with specific embodiments. It should be noted that the specific embodiments are intended to explain the present invention rather than to limit it.
[0062] In the following examples and comparative examples, approximately appropriate amounts of bisoprolol impurity A, bisoprolol impurity B, bisoprolol impurity E, bisoprolol impurity K, bisoprolol impurity L, bisoprolol impurity R, bisoprolol impurity S, bisoprolol impurity T, bisoprolol impurity G, bisoprolol impurity 8, bisoprolol impurity 10, amlodipine impurity A, amlodipine impurity B, amlodipine impurity D, amlodipine impurity E, amlodipine impurity F, amlodipine impurity G, amlodipine impurity H, amlodipine impurity J, amlodipine impurity K, amlodipine impurity L, and amlodipine and fumaric acid addition impurities were taken, accurately weighed, dissolved in solvents and diluted to prepare solutions containing approximately 0.1 mg per 1 ml, respectively, as stock solutions of each impurity.
[0063] Take appropriate amounts of bisoprolol fumarate reference substance and amlodipine besylate reference substance, weigh them accurately, dissolve them in solvents and dilute them to make solutions containing approximately 0.1 mg of bisoprolol fumarate and 0.1 mg of amlodipine per 1 ml, respectively, as stock solutions of main component reference substances.
[0064] Accurately measure 1 ml of the above impurity stock solution and the main component reference stock solution, place them in different 100 ml volumetric bottles, dilute to the scale with solvent, shake well, and use them as the impurity peak positioning solution and the main component peak positioning solution.
[0065] Take about 50 mg of bisoprolol fumarate and about 70 mg of amlodipine besylate (approximately equivalent to 50 mg of amlodipine), accurately weigh, and place in a 100 ml volumetric flask. Take 1 ml of each impurity stock solution, place in this 100 ml volumetric flask, shake well, and use this as the mixed peak positioning solution.
[0066] Accurately measure 1 ml of the above impurity stock solution and the main component reference stock solution, place them in the same 100 ml volumetric flask, dilute to the scale with solvent, shake well, and use as the mixed reference peak positioning solution.
[0067] Take about 3.28 mg of fumaric acid and 4.83 mg of benzenesulfonic acid respectively, weigh accurately, put into different 25 ml volumetric flasks, add appropriate amount of solvent, stir with a magnetic stirrer for 30 minutes, cool, dilute to the scale with solvent, shake well, and use them as fumaric acid peak positioning solution and benzenesulfonic acid peak positioning solution.
[0068] Example 1
[0069] (1) Test solution: Take 20 tablets of this product, accurately weigh, grind into powder, take about 375 mg of fine powder (equivalent to 12.5 mg of bisoprolol fumarate and 12.5 mg of amlodipine), place in a 25 ml volumetric flask, add 20 ml of solvent, stir with a magnetic stirrer for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, cool, dilute to scale with solvent, shake well, and filter.
[0070] (2) Chromatographic conditions: Use octadecylsilane bonded silica gel as filler (XB-C18, 4.6 mm × 250 mm, 5 μm or chromatographic column of equivalent performance produced by Yuexu Technology Co., Ltd.); use 0.05 mol / L diammonium hydrogen phosphate solution containing 0.05% perchloric acid (pH adjusted to 4.5 with phosphoric acid) as mobile phase A, and use acetonitrile containing 0.1% phosphoric acid as mobile phase B, and perform gradient elution according to the table below; column temperature is 30°C; flow rate is 1.0 ml per minute; detection wavelengths are 226 nm and 254 nm (impurity BIS-2); injection volume is 20 μl.
[0071]
[0072] The test results are as follows Figure 1 shown.
[0073] Comparative Example 1
[0074] With reference to the import registration standard, chromatographic column: GL Sciences Inerysil C8 (4.6mm×150mm, 5μm); mobile phase A: perchloric acid solution (take 1000ml of water and adjust the pH to 2.8 with 35% perchloric acid solution); mobile phase B: acetonitrile-35% perchloric acid solution (1000:0.6); column temperature: 60℃; detection wavelength: 226nm, 254nm; flow rate: 1.0ml / min; injection volume: 100μl.
[0075]
[0076] Accurately measure 100 μl of each impurity peak positioning solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 2 shown.
[0077] The test results showed that the separation of impurities was poor and the peak shape was poor. Consider replacing the chromatographic column and extending the gradient elution.
[0078] Comparative Example 2
[0079] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: perchloric acid solution (take 1000ml of water and adjust the pH to 2.8 with 35% perchloric acid solution); mobile phase B: acetonitrile-35% perchloric acid solution (1000:0.6); column temperature: 45℃; flow rate: 1.0ml / min; injection volume: 100μl.
[0080]
[0081] Accurately measure 100 μl of each impurity peak positioning solution and mixed solution, inject them into the liquid chromatograph, and record the chromatogram. Figure 3 shown.
[0082] The test results show that the impurity peak shape is poor, and optimization is considered with reference to the relevant substances of bisoprolol tablets in the Chinese Pharmacopoeia.
[0083] Comparative Example 3
[0084] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH to 4.5 with phosphoric acid); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 225nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0085] Table 3 Gradient elution program of Comparative Example 2
[0086]
[0087] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 4 shown.
[0088] The experimental results showed that the peak shape was improved, but the separation between the main peak of bisoprolol and impurities was poor, and the method optimization was considered by extending the gradient conditions.
[0089] Comparative Example 4
[0090] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH to 4.5 with phosphoric acid); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 225nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0091]
[0092] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 5 shown.
[0093] The test results showed that the separation degree of impurities was poor at the retention time of about 40 minutes, and the method optimization should be considered by reducing the proportion of organic phase.
[0094] Comparative Example 5
[0095] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH value to 4.5 with phosphoric acid); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0096]
[0097] Accurately measure 20 μl of each impurity peak positioning solution and mixed solution, inject them into the liquid chromatograph, and record the chromatogram. Figure 6 shown.
[0098] The test results show that the impurities are well separated from the main component and the peak shape is good. However, the adduct and the amlodipine impurity F are not separated. Consider adjusting the pH value to 3.0 and increasing the organic phase change to see if they can be separated.
[0099] Comparative Example 6
[0100] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH to 3.0 with phosphoric acid); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0101]
[0102]
[0103] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 7 shown.
[0104] The test results show that the impurity separation becomes worse and cannot meet the baseline separation requirements. Consider extending the gradient time and optimizing the method.
[0105] Comparative Example 7
[0106] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH to 3.0 with phosphoric acid); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0107]
[0108] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Figure 8 shown.
[0109] The test results showed that the impurities were not baseline separated. We considered adjusting the pH values to see how they separated and continue to optimize the method.
[0110] Comparative Example 8
[0111] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH value to 3.2, 3.5, 3.8, 4.0, 4.2, 4.5 with phosphoric acid or sodium hydroxide); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0112]
[0113] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Fig. 9 shown.
[0114] The test results show that different pH values have a great influence on the separation of impurities (about 40 minutes of impurities), and the separation is optimal when the pH value is 3.0. Consider further adjusting the pH value and changing the mobile phase ratio to further optimize the chromatographic conditions.
[0115] Comparative Example 9
[0116] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH value to 3.8 or 2.0 with phosphoric acid or sodium hydroxide); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0117]
[0118]
[0119] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Fig.10 shown.
[0120] The test results show that the separation is better when the pH value of the mobile phase is 3.8, and the impurities are not baseline separated. Consider further reducing the proportion of organic phase for optimization.
[0121] Comparative Example 10
[0122] Chromatographic column: XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L phosphate buffer (take 6.6g of diammonium hydrogen phosphate, add 1000ml of water, and adjust the pH value to 3.8 with phosphoric acid or sodium hydroxide); mobile phase B: acetonitrile; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0123]
[0124] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Fig.11 shown.
[0125] The test results show that the impurities are well separated, but the impurities are basically overlapped (about 21 minutes). After the above exploration, it is found that the higher the pH value of the mobile phase before 20 minutes, the better the separation is. Therefore, it is considered to add acid to mobile phase B in accordance with the import registration standard.
[0126] Comparative Example 11
[0127] Chromatographic column: Yuexu XB-C18 (4.6mm×250mm, 5μm); mobile phase A: 0.05mol / L diammonium hydrogen phosphate solution containing 0.05% perchloric acid (the pH value was adjusted to 4.5 with phosphoric acid); mobile phase B: acetonitrile containing 0.1% phosphoric acid; column temperature: 30℃; detection wavelength: 226nm; flow rate: 1.0ml / min; injection volume: 20μl.
[0128]
[0129] Accurately measure 20 μl of the mixed solution, inject it into the liquid chromatograph, and record the chromatogram. Fig.12 shown.
[0130] Experimental Example 1: Specificity Test
[0131] Forced degradation test protocol
[0132] Bisoprolol levoamlodipine tablets were subjected to destruction tests under unconventional conditions, and the specificity of the related substance inspection method for bisoprolol levoamlodipine tablets was investigated using a diode array detector (DAD), with emphasis on the separation of the destruction product peak and the main peak, the purity of the main component peak, etc. The optimal detection wavelength was determined by comparing the impurity amounts at different wavelengths.
[0133] Because the amlodipine peak of bisoprolol levoamlodipine tablets is overloaded at low wavelengths (higher concentration) at a concentration of 0.5 mg / ml (calculated as amlodipine), the amlodipine chromatographic peak is flat and the peak purity is inaccurate. Therefore, the concentration of the related substances specific to bisoprolol levoamlodipine tablets was adjusted to 0.3 mg / ml (calculated as amlodipine) to accurately calculate the main peak purity.
[0134] Undestroyed: Take about 225 mg of bisoprolol and amlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), put it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, cool, dilute to the scale with solvent, shake well, filter, and use as the undestroyed solution.
[0135] Acid destruction: Take about 225 mg of bisoprolol levoamlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), place it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, add 1 ml of 1 mol / L hydrochloric acid solution, shake well, place in a 90°C oven, leave for 1.5 hours, take out, cool, add 1 ml of 1 mol / L sodium hydroxide solution, dilute to the scale with solvent, shake well, filter, and use as the acid destruction solution.
[0136] Alkali destruction: Take about 225 mg of bisoprolol and amlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), put it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, add 1.5 ml of 1 mol / L sodium hydroxide solution, shake well, put it in a 90°C oven for 0.5 hour, take it out, let it cool, add 1.5 ml of 1 mol / L hydrochloric acid solution, dilute to the scale with solvent, shake well, filter, and use as the alkali destruction solution.
[0137] Oxidative destruction: Take about 225 mg of bisoprolol-levoamlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), place it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, add 3 drops of 30% hydrogen peroxide solution, shake well, place in a 90°C oven, leave for 0.5 hour, take out, cool, dilute to the scale with solvent, shake well, filter, and use as the oxidative destruction solution.
[0138] High temperature destruction: Take about 225 mg of bisoprolol and amlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), put it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, put it in a 90°C oven for 6 hours, take it out, cool it, dilute it to the scale with solvent, shake it well, filter it, and use it as the high temperature destruction solution.
[0139] Photodestruction: Take about 225 mg of bisoprolol and amlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), place it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, place it in a 4500 lx ± 500 lx light box for 7 days, dilute to the scale with solvent, shake well, filter, and use as the photodestruction solution.
[0140] Ultraviolet light destruction: Take about 225 mg of bisoprolol and amlodipine tablets fine powder (equivalent to 7.5 mg of bisoprolol fumarate and 7.5 mg of amlodipine), put it in a 25 ml volumetric flask, add 20 ml of solvent, shake vigorously for 30 minutes to dissolve the bisoprolol fumarate and amlodipine, put it in a 500W±50W ultraviolet light box for 1 hour, cool, dilute to the scale with solvent, shake well, filter, and use as the ultraviolet light destruction solution.
[0141] Take about 207 mg of solvent and blank auxiliary material, and perform a blank test according to the above method to facilitate the identification of impurities.
[0142] Accurately measure 20 μl of each of the above solutions, inject them into a liquid chromatograph, detect with a DAD detector in the wavelength range of 200 nm to 400 nm, and record the chromatogram.
[0143] The chromatogram at 226nm wavelength and the spectral absorption diagram of the main components were extracted. Under the forced degradation test, the main peak purity of each destruction solution was greater than 0.995. The degradation impurities of amlodipine were attributed to the known impurities and amlodipine besylate raw materials, and the degradation impurities of bisoprolol were attributed to the known impurities and bisoprolol fumarate raw materials. The results of the forced degradation test (preparation-226nm) are shown below.
[0144]
[0145]
[0146] The test graph is as follows Fig.13 As shown, the corresponding known impurities and main component peaks are shown below.
[0147]
[0148]
[0149] Take appropriate amounts of bisoprolol impurity A, bisoprolol impurity B, bisoprolol impurity E, bisoprolol impurity K, bisoprolol impurity L, bisoprolol impurity R, bisoprolol impurity S, bisoprolol impurity T, bisoprolol impurity G, bisoprolol impurity 8, bisoprolol impurity 10, amlodipine impurity A, amlodipine impurity B, amlodipine impurity D, amlodipine impurity E, amlodipine impurity F, amlodipine impurity G, amlodipine impurity H, amlodipine impurity J, amlodipine impurity K, amlodipine impurity L, and amlodipine and fumaric acid addition impurities, accurately weigh, dissolve in solvents respectively, and dilute to prepare solutions containing approximately 0.1 mg per 1 ml, which are used as stock solutions of each impurity.
[0150] Take appropriate amounts of bisoprolol fumarate reference substance and amlodipine besylate reference substance, weigh them accurately, dissolve them in solvents and dilute them to make solutions containing approximately 0.1 mg of bisoprolol fumarate and 0.1 mg of amlodipine per 1 ml, respectively, as stock solutions of main component reference substances.
[0151] Accurately measure 1 ml of the above impurity stock solution and the main component reference stock solution, place them in different 100 ml volumetric bottles, dilute to the scale with solvent, shake well, and use them as the impurity peak positioning solution and the main component peak positioning solution.
[0152] Take about 50 mg of bisoprolol fumarate and about 70 mg of amlodipine besylate (approximately equivalent to 50 mg of amlodipine), accurately weigh, and place in a 100 ml volumetric flask. Take 1 ml of each impurity stock solution, place in this 100 ml volumetric flask, shake well, and use this as the mixed peak positioning solution.
[0153] Accurately measure 1 ml of the above impurity stock solution and the main component reference stock solution, place them in the same 100 ml volumetric flask, dilute to the scale with solvent, shake well, and use as the mixed reference peak positioning solution.
[0154] Take about 3.28 mg of fumaric acid and 4.83 mg of benzenesulfonic acid respectively, weigh accurately, put into different 25 ml volumetric flasks, add appropriate amount of solvent, stir with a magnetic stirrer for 30 minutes, cool, dilute to the scale with solvent, shake well, and use them as fumaric acid peak positioning solution and benzenesulfonic acid peak positioning solution.
[0155]
[0156]
[0157] Experimental Example 2: Sensitivity test.
[0158] Take appropriate amounts of each impurity and main component, weigh them accurately, and dilute them with solvent to make solutions of a series of concentrations. The signal-to-noise ratio (S / N) ≈ 10 is the quantification limit, and the S / N (signal-to-noise ratio) ≈ 3 is the detection limit.
[0159]
[0160]
[0161] The test results show that the limits of each impurity / limit of quantitation are all greater than 5, and the detection sensitivity of this method is good.
[0162] Experimental Example 3: Linearity Test
[0163] Take appropriate amounts of bisoprolol impurity A, bisoprolol impurity B, bisoprolol impurity E, bisoprolol impurity K, bisoprolol impurity L, bisoprolol impurity R, bisoprolol impurity S, bisoprolol impurity T, bisoprolol impurity G, bisoprolol impurity 8, bisoprolol impurity 10, amlodipine impurity A, amlodipine impurity B, amlodipine impurity D, amlodipine impurity E, amlodipine impurity F, amlodipine impurity G, amlodipine impurity H, amlodipine impurity J, amlodipine impurity K, amlodipine impurity L, and the addition impurity of amlodipine and fumaric acid, accurately weigh them, dissolve them in solvents respectively, and dilute them to prepare solutions containing about 0.1 mg per 1 ml, which are used as stock solutions of each impurity.
[0164] Accurately measure 2 ml of the above impurity stock solution, place it in a 50 ml volumetric flask, dilute it to the scale with solvent, shake well, and use it as the linear stock solution; accurately measure 2 ml, 2.5 ml, 4 ml, 5 ml, 6 ml, 7.5 ml, and 10 ml of the linear stock solution, place them in different 20 ml volumetric flasks, dilute them to the scale with solvent, shake well, and use them as 0.4 μg / ml, 0.5 μg / ml, 0.8 μg / ml, 1.0 μg / ml, 1.2 μg / ml, 1.5 μg / ml, and 2 μg / ml concentration linear series solutions, respectively.
[0165] Accurately measure 1 ml of bisoprolol impurity stock solution respectively, place in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, and prepare as 5 μg / ml bisoprolol linear series solutions.
[0166] Accurately measure 1 ml of the amlodipine impurity stock solution respectively, place it in a 20 ml volumetric flask, dilute to the scale with solvent, shake well, and prepare them as a series of amlodipine horizon solutions with a concentration of 5 μg / ml.
[0167] Accurately measure 1.5 ml of bisoprolol impurity stock solution respectively, place in a 25 ml volumetric flask, dilute to the scale with solvent, shake well, and prepare as 6 μg / ml bisoprolol linear series solutions.
[0168] Accurately measure 1.5 ml of the amlodipine impurity stock solution respectively, place it in a 25 ml volumetric flask, dilute to the scale with solvent, shake well, and prepare them as a series of amlodipine horizon solutions with a concentration of 6 μg / ml.
[0169] Take the quantitative limit solution as the quantitative limit linear solution.
[0170] Accurately measure 20 μl of each of the above linear series concentration solutions, inject them into the liquid chromatograph, record the chromatogram, and perform linear regression with concentration versus peak area. The linearity test results are as follows:
[0171]
[0172]
[0173] Experimental Example 4: Control Solution Repeatability Test
[0174] Accurately measure 2 ml of the main component reference substance and the stock solution of each impurity (100 μg / ml), place them in the same 100 ml volumetric flask, dilute to the scale with solvent, shake well, and use as the reproducible solution of the impurity reference substance (2 μg / ml).
[0175] Accurately measure 20 μl of each of the above solutions, inject into the liquid chromatograph, repeat the injection 6 times, and record the chromatogram. The repeatability test results are shown below.
[0176]
[0177] The test results show that the repeatability solutions of the reference substance (1μg / ml, 2μg / ml, control concentration solution) were injected repeatedly 6 times, the RSD% of the retention time was less than 1%, and the RSD% of the peak area was less than 3%. The repeatability of the repeatability solutions of the reference substance (1μg / ml, 2μg / ml, control concentration solution) of this product is good.
[0178] Experimental Example 5: Solution Stability
[0179] Accurately measure 2 ml of the main component reference substance and the stock solution of each impurity (100 μg / ml), place them in the same 100 ml volumetric flask, dilute to the scale with solvent, shake well, and use as the impurity reference substance stability solution (2 μg / ml).
[0180] Accurately measure 5 ml of the reference substance stability solution (2 μg / ml), place it in a 10 ml volumetric flask, dilute to the mark with solvent, shake well, and use this as the impurity reference substance stability solution (1 μg / ml).
[0181] Accurately measure 2.5 ml, 2.5 ml, 1.5 ml and 2.5 ml of the stock solutions (100 μg / ml) of bisoprolol fumarate reference substance, amlodipine besylate reference substance, bisoprolol impurity A and bisoprolol impurity K respectively, place them in a 10 ml volumetric flask, dilute to the scale with solvent, shake well and use as the control stability solution.
[0182] The samples were placed at room temperature for 3 days. At 0 hour, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 2 days and 3 days, 20 μl was accurately measured and injected into the liquid chromatograph to record the chromatogram.
[0183] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A liquid chromatography test method for related substances in bisoprolol levamlodipine tablets, characterized in that: include: Grind the bisoprolol levamlodipine tablets, stir, dilute to volume, centrifuge, take the supernatant, filter, and obtain the test solution; Prepare reference solutions of various impurities respectively; The test solution and the reference solution are tested by liquid chromatography to confirm the content of each impurity; Among them, the impurities are amlodipine impurities A, B, D, E, F, G, H, J, K, L, bisoprolol impurities A, B, E, G, L, R, S, T, 8, 10, and amlodipine and fumaric acid addition impurities.
2. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The chromatographic column uses octadecylsilane bonded silica gel as a filler, which is a C18 column.
3. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: Mobile phase A was 0.05 mol / L diammonium hydrogen phosphate solution containing 0.05% perchloric acid, and the pH value was adjusted to 4.5 with phosphoric acid; mobile phase B was acetonitrile containing 0.1% phosphoric acid.
4. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The detection wavelengths are 226nm and 254nm.
5. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The column temperature was 30°C.
6. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets according to claim 1, characterized in that: The flow rate was 1.0 ml per minute.
7. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The injection volume was 20 μl.
8. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The gradient elution program was as follows: 0-25 min, mobile phase A 90%-65%; 25-45 min, mobile phase A 65%-30%; 45-60 min, mobile phase A 30%; 60-61 min, mobile phase A 30%-90%; 61-75 min, mobile phase A 90%, where % is the volume percentage.
9. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets as claimed in claim 1, characterized in that: The concentration of the test product is 0.08%-1.2%.
10. The liquid chromatography test method for related substances in bisoprolol levamlodipine tablets according to claim 1, characterized in that: The concentration of the reference substance is 0.08%-1.2%.
